The handling of highly potent active pharmaceutical ingredients (HPAPIs) is on the rise in many industries. At the same time, demands on equipment and processes are rising. A clear understanding of when a product is considered “highly potent” and how active ingredients can be classified according to OEL and OEB levels is crucial for safety and efficiency. Without this clarity, there is a risk of misinterpretation regarding isolators, filling lines, freeze-drying, and building services – with implications for operator safety, product quality, and regulatory compliance.
Traditional, purely aseptic approaches are insufficient for HPAPIs because even low concentrations can pose significant health risks to operating personnel. Inadequately defined exposure limits lead to planning errors: Overly generous assumptions drive up costs, while overly strict assumptions compromise safety. Particularly critical are scenarios where the risk level varies depending on the dosage form – such as non-critical liquid formulations that form highly active dusts after freeze-drying. Without a clear classification, containment, airflow, filtration, and cleaning strategies cannot be designed with precision.
With personalized medicine, smaller batches, and a growing proportion of highly potent substances, product variability is increasing. Reliable OEL data is often lacking in early development phases. Companies therefore need robust classification concepts that mitigate development uncertainties while still being regulatorily sound. Complexity is increasing because both liquid and lyophilization routes are increasingly being run on a single line – including different exposure scenarios.
Two key parameters are central:
In the absence of OEL data, OEB serves as a practical, internal company classification. OEB also promotes clarity within the project team: A value such as “OEB 4” can be communicated more quickly than a µg/m³ range. Technical specifications – such as isolator level, pressure cascades, filter design, wash-down, and bio-decontamination – are derived from this and, if necessary, differentiated on a substance-specific basis for liquid versus lyophilized materials.
A reliable OEL/OEB classification forms the foundation of every HPAPI facility. It translates active ingredient properties into concrete, measurable requirements for technology, processes, and infrastructure – and enables both safety and cost-effectiveness to be achieved simultaneously.
Optima establishes the active ingredient classification early in the project: During the consulting phase, OEL/OEB, dosage forms, and application scenarios are identified. From these, containment levels, pressure cascades, and filtration and cleaning strategies are derived and verified through simulations (airflow, bio-decontamination, wash-down). This results in a holistically coordinated, qualifiable facility concept.